ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1663

The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia

Khalid Almutairi1, Johannes Nossent1, David Preen1, Helen Keen2 and Charles Inderjeeth3, 1University of Western Australia, Perth, Australia, 2University of Western Australia, Daglish, Australia, 3University of Western Australia, Nedlands, Perth, Australia

Meeting: ACR Convergence 2021

Keywords: Comorbidity, longitudinal studies, Mortality, population studies, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of published literature on the mortality and morbidity rates in RA patients, despite the significant morbidity and mortality burden on health care costs due to RA. Linked data is the preferred method to estimate morbidity and mortality outcomes as they provide the best case ascertainment. The aim of this study was to describe temporal changes in mortality rates for patients with Rheumatoid arthritis (RA) in relation to comorbidity accrual from 1980-2015 in Western Australia (WA).

Methods: Using population-level linked data from WA health administrative datasets (hospital morbidity, emergency department and death data), we followed 17,125 RA patients (ICD-10-AM M05.00–M06.99, ICD-9-CM 714) from 1980- 2015. Comorbidity was ascertained using the Charlson Comorbidity Index (CCI). Mortality rate ratios (MRR) were calculated per decade between the RA cohort and the WA general population by direct age standardisation method, while temporal trends of comorbidities and in-hospital mortality were estimated per 1000 hospital separations in three consecutive decades.

Results: During 356,069 patient-years, a total of 8955 (52%) deaths occurred in the RA cohort. The leading causes of deaths were cardiovascular diseases 2386 (26.6%), cancer 1511 (16.8%), rheumatic diseases 519 (5.8%), chronic pulmonary disease 491 (5.5%), dementia 269 (3.0%) and diabetes 235 (2.6%). The highest prevalence of comorbidity (688.6 per 1000 separations) was in the period 1991-2000 following a 1.3% average annual increase since 1980. In-hospital mortality rate was also highest (26.7 deaths per 1000 separations) in the same period. After 2001, both RA comorbidity and mortality rates decreased annually by -0.5% and -4.8%, respectively, with annual changes of -4.4% to -2% and from 2011- 2015, respectively. The overall mortality rate in RA patients after age adjustment was 2.5-times (95%CI: 2.52-2.65) higher than the general population between 1980- 2015 and 1.5-times (95%CI: 1.39-1.81) for the period 2011-2015.

Conclusion: The annual comorbidity prevalence and mortality rates in WA have decreased significantly since 2001, reflecting improvements in the management of RA and comorbidity. Nonetheless, the mortality rate in RA patients in WA remains 1.5-times higher than their community counterparts suggesting that there is room to achieve further improvements.

Table 1: Mortality rates observed among patients with rheumatoid arthritis, based on Charlson Comorbidity Index, per 1000 hospital separations, Western Australia hospitals (1980_2015).


Disclosures: K. Almutairi, None; J. Nossent, None; D. Preen, None; H. Keen, Roche, 6, Abbvie, 6, Roche, 12, education/travel; C. Inderjeeth, None.

To cite this abstract in AMA style:

Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-influence-of-comorbidity-on-mortality-in-patients-with-rheumatoid-arthritis-1980-2015-a-longitudinal-population-based-study-in-western-australia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-influence-of-comorbidity-on-mortality-in-patients-with-rheumatoid-arthritis-1980-2015-a-longitudinal-population-based-study-in-western-australia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology